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Abstract 
Background: Non-healing wounds are a major global health concern and account for the majority of non-traumatic 
limb amputations worldwide. However, compared to standard care practices, few advanced therapeutics effectively 
resolve these injuries stemming from cardiovascular disease, aging, and diabetes-related vasculopathies. While matrix 
turnover is disrupted in these injuries, debriding enzymes may promote healing by releasing matrix fragments that 
induce cell migration, proliferation, and morphogenesis, and plasma products may also stimulate these processes. 
Thus, we created matrix- and plasma-derived peptides, Comb1 and UN3, which induce cellular injury responses 
in vitro, and accelerate healing in rodent models of non-healing wounds. However, the effects of these peptides in 
non-healing wounds in diabetes are not known. Here, we interrogated whether these peptides stimulate healing in a 
diabetic porcine model highly reminiscent of human healing impairments in type 1 and type 2-diabetes.
Methods: After 3–6 weeks of streptozotocin-induced diabetes, full-thickness wounds were surgically created on the 
backs of adult female Yorkshire swine under general anesthesia. Comb1 and UN3 peptides or sterile saline (nega-
tive control) were administered to wounds daily for 3–7 days. Following sacrifice, wound tissues were harvested, and 
quantitative histological and immunohistochemical analyses were performed for wound closure, angiogenesis and 
granulation tissue deposition, along with quantitative molecular analyses of factors critical for angiogenesis, epitheli-
alization, and dermal matrix remodeling.
Results: Comb1 and UN3 significantly increase re-epithelialization and angiogenesis in diabetic porcine wounds, 
compared to saline-treated controls. Additionally, fluorescein-conjugated Comb1 labels keratinocytes, fibroblasts, and 
vascular endothelial cells in porcine wounds, and Far western blotting reveals these cell populations express multiple 
fluorescein-Comb1-interacting proteins in vitro. Further, peptide treatment increases mRNA expression of several 
pro-angiogenic, epithelializing, and matrix-remodeling factors, importantly including balanced inductions in matrix 
metalloproteinase-2, -9, and tissue inhibitor of metalloproteinases-1, lending further insight into their mechanisms.
Conclusions: Comb1 and UN3 stimulate wound resolution in diabetic Yorkshire swine through upregulation of 
multiple reparative growth factors and cytokines, especially matrix metalloproteinases and inhibitors that may aid in 
reversing the proteolytic imbalance characteristic of chronically inflamed non-healing wounds. Together, these pep-
tides should have great therapeutic potential for all patients in need of healing, regardless of injury etiology.
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Background
Non-healing wounds associated with cardiovascular dis-
ease, aging, and diabetes are a major global healthcare 
issue. The number of patients with diabetes worldwide is 
anticipated to exceed 400 million by 2025 [1], and at least 
15  % of these patients will develop diabetic foot ulcers 
(DFU) during their lifetime [2]. These wounds directly 
precede 80 % of nontraumatic limb amputations, globally 
[3], with an annual mortality estimated to be greater than 
that of several major cancers [4]. The greatest increases 
in diabetes are expected in regions with limited health-
care access; here, patients may have less glycemic con-
trol due to the expense of insulin and other medicines, 
precipitating higher rates of peripheral neuropathy, DFU, 
and ultimately amputation [2]. Moreover, despite the 
predicted rise in DFU prevalence, along with cardiovas-
cular disease- and aging-associated non-healing wounds, 
there remain few advanced therapeutics that effectively 
improve healing outcomes compared to standard care 
practices, including debridement and mechanical off-
loading [5]. Thus, there is a vastly unmet clinical need for 
safe, effective, and affordable chronic wound treatments 
across the globe.
The modest outcomes observed following treatment 
with current molecular medicines may stem from the 
inflamed, protease-rich DFU microenvironment [6], 
which deprives cells of growth factors and matrix-derived 
signals necessary for tissue repair [7, 8] and may degrade 
exogenously applied growth factor-based therapeutics 
such as becaplermin [9]. Hence, molecular interventions 
that resist proteolytic cleavage, as well as normalize the 
chronic wound protease-to-inhibitor ratio, are innova-
tive strategies that may resolve DFU. Intriguingly, matrix-
remodeling enzymes such as Clostridial collagenase, and 
matrix-derived preparations such as platelet-rich plasma 
(PRP), each have been demonstrated to induce tissue 
repair in DFU [10, 11], suggesting these entities promote 
healing through mechanisms unimpeded by the chronic 
wound protease burden. Thus, in our efforts to uncover 
these mechanisms and develop advanced therapeutics, 
we identified bioactive peptides liberated from Clostrid-
ial collagenase-digested vascular endothelial extracellu-
lar matrix (ECM) and thrombin-derived peptides in PRP 
that stimulate cell migration, proliferation, and microvas-
cular morphogenesis [12, 13]. In turn, we created short, 
protease-resistant, combinatorial peptides comprised of 
the individual ECM (Comb1) and PRP peptides (UN3), 
which further augment endothelial cell proliferation and 
morphogenesis, and post-injury keratinocyte migra-
tion in  vitro [12, 13]. Moreover, each of these com-
binatorial peptides enhances wound vascularization, 
granulation tissue formation, and re-epithelialization in 
cyclophosphamide-treated, healing-impaired mice, and 
wounds treated with Comb1 and UN3, together, display 
greater angiogenesis and a thicker epidermis than those 
treated with either peptide alone [13].
Based on these results, we hypothesized Comb1 and 
UN3 would induce healing in diabetic wounds. Here, we 
demonstrate Comb1 and UN3 stimulate post-injury angi-
ogenesis, granulation tissue formation, and re-epithelial-
ization in a pre-clinical swine model of impaired healing, 
which is highly reminiscent and parallels the human 
pathophysiologic responses to injury observed in chron-
ically-impaired, non-healing wounds [14]. Additionally, 
fluorescein isothiocyanate (FITC)-conjugated Comb1 
labels cell populations in diabetic porcine wound tissues, 
including fibroblasts and endothelial cells in granulation 
tissue and keratinocytes present near the wound edge, 
as well as several millimeters distal to the injury. Further, 
FITC-Comb1 interacts with multiple proteins isolated 
from adult human keratinocytes propagated under low 
Ca2+ conditions and elevated temperature (HaCaT), adult 
human dermal microvascular endothelial cells (HMVEC), 
and human foreskin fibroblasts (HFF), with binding pat-
terns dependent on cellular responses to injury in vitro. 
Finally, Comb1 and UN3 significantly stimulate mRNA 
expression of pro-angiogenic growth factors and recep-
tors, including vascular endothelial growth factor-A 
(VEGFA), VEGF receptor 1 and 2 (VEGFR1/2), and 
fibroblast growth factor-2 (FGF2), immune and stem cell 
chemoattractants including stromal cell-derived factor 
1α (SDF1α) and chemokine (C-X-C motif ) receptor-4 
(CXCR4), and re-epithelialization factors including epi-
dermal growth factor (EGF), heparin-binding EGF-like 
(HB-EGF), and EGFR in a time- and tissue-specific pat-
tern in diabetic porcine tissues. Importantly, peptide 
treatment induces matrix metalloproteinase-2 (MMP2), 
MMP9, and tissue inhibitor of metalloproteinases-1 
(TIMP1) mRNA expression, which may aid in restoring 
the protease/inhibitor balance to promote healing. Over-
all, these bioactive peptides may be a novel therapeutic 





Adult female Yorkshire swine weighing 50–60  kg were 
made diabetic by intravenous administration of strepto-
zotocin (STZ, Teva Pharmaceuticals, Petah Tikva, Israel) 
at a dose of 150 mg/kg as described [15]. Blood glucose 
levels were obtained twice daily using a OneTouch Ultra-
Mini glucometer (LifeScan, Inc., Milpitas, CA), with dia-
betes confirmed by glucose levels greater than 200  mg/
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dL; insulin was administered twice daily on a sliding scale 
to maintain levels between 250 and 600 mg/dL, to model 
poor glycemic control.
Full thickness excisional wounding and post‑injury 
treatments
Following 3–6  weeks of diabetic induction, animals 
underwent Tufts University IACUC-approved dorsal 
wounding surgeries: after anesthesia induction with 
a telazol/ketamine/xylazine cocktail, dorsal hair was 
removed with depilatory cream, followed by shaving. 
Under general anesthesia with isoflurane, the paraspinal 
area was prepared and draped sterilely, and full-thickness 
(5.0 mm deep) excisional wounds were created in the ani-
mals’ backs using sterile, stainless steel biopsy punches 
(8.0  mm-diameter) or a sterile No. 11 surgical blade 
(2.0 cm × 2.0 cm square wounds). Following hemostasis 
by manual compression, wounds were covered using 10 % 
compound tincture of benzoin adhesive and Tegaderm 
transparent dressing (3  M, St. Paul, MN) and animals 
were placed in protective jackets. Comb1 (1.0  mg/mL) 
and UN3 (284 μg/mL) peptides (synthesized by Anaspec, 
Fremont, CA) were suspended in autoclaved 4  % car-
boxymethylcelluose and administered to wounds daily by 
injection beneath the Tegaderm bandage, for a period of 
3–7 days. Sterile saline served as a negative control.
Tissue harvesting
Immediately following euthanasia, dorsal wounds, 
including the underlying subcutaneous tissue and fas-
cia, together with an approximately 1  cm perimeter of 
uninjured cutaneous tissue bordering the wound, were 
harvested. Wounds were bisected using a sterile surgi-
cal blade. Half of each wound was fixed in buffered 4 % 
formaldehyde and reserved for histology. A 1 mm-thick 
section was removed from the remaining half of each 
wound, partitioned into granulation tissue, hypodermis, 
and adjacent, non-wounded dermis and epidermis using 
a sterile, stainless steel razor blade, and each piece of tis-
sue was placed in RNAlater RNA stabilization reagent 
(Qiagen, Venlo, NL). The remaining tissues were placed 
in large cryovials, snap-frozen in liquid nitrogen, and 
reserved for immunohistochemistry.
Quantitative histology and immunohistochemistry 
of healing responses
Histology, immunohistochemistry, and microscopy of fixed, 
paraffin‑embedded tissues
After fixation in buffered formaldehyde for 72 h, wounds 
were embedded in paraffin, cut into 5  μm-thick sec-
tions, and stained with hematoxylin and eosin (H&E) or 
Masson’s trichrome. Microscopic imaging of H&E and 
trichrome-stained sections was performed as described 
[13].
Immunhistochemistry and microscopy of fresh frozen tissues
Flash frozen pieces of diabetic porcine wounds were 
re-equilibrated in PBS-buffered 0.5  % formaldehyde 
and 15 % sucrose for 2 days at 4C, followed by 2 days in 
PBS-buffered 0.5 % formaldehyde and 30 % sucrose, and 
embedded in Tissue-Tek OCT compound (VWR, Rad-
nor, PA). 18  μm-thick sections were cut and placed on 
Superfrost Plus glass slides (Fisher Scientific, Pittsburgh, 
PA). Fluorescent immunohistochemistry using mouse 
anti-CD31 (1:200, Novus Biologicals, Littleton, CO) and 
rabbit anti-HSPG (1:200), and subsequent microscopy 
were performed as described [13].
Labeling tissue with FITC‑conjugated Comb1
18  μm-thick sections of fresh frozen saline-treated por-
cine wounds were blocked with PBS containing 5  % 
normal goat serum (NGS) for 1  h at room temperature 
in a humidified chamber, then incubated with 100  nM 
FITC-Comb1 in 5 % NGS, protected from light. Fluores-
cent immunohistochemistry using rabbit anti-FITC pri-
mary antibody (1:100, Life Technologies) and subsequent 
microscopy were performed using methods described 
[13]. Slides incubated with 5 % NGS alone served as neg-
ative controls.
Quantitative analysis of wound healing responses
Composite images of H&E, trichrome, and immuno-
labeled wounds were created as described [13]. Per-
cent wound closure was determined by dividing the 
total linear distance of keratinocyte migration from 
the wound edge by the total width of each wound, each 
measured using the NIH ImageJ freehand line tool. 
Angiogenic responses were quantified from merged 
immunofluorescence images: total wounded area, defined 
as the histologically apparent interruption in normal skin 
morphology, and granulation tissue area, defined as the 
area with dual positivity for CD31 and HSPG, were quan-
tified using the NIH ImageJ freehand tool, and the per-
centage of granulation tissue occupying the wound was 
calculated; microvascular density within the granulation 
tissue was calculated by measuring CD31/HSPG co-
localization intensity using NIH ImageJ [13], and normal-
izing against the granulation tissue area.
Peptide binding studies
Cell culture
Primary adult HMVEC (Lonza Bioscience, Walkers-
ville, MD) were cultured in Endothelial Basal Medium-2 
(Lonza) supplemented with 5 % fetal bovine serum (FBS) 
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and the growth factors contained within the EGM2-MV 
kit (Lonza), according to the manufacturer’s instruc-
tions. HFF and HaCaT (gifts from the laboratory of Dr. 
Jonathan Garlick, Tufts) were grown in DMEM sup-
plemented with 10  % FBS (Atlanta Biologicals, Atlanta, 
GA), 1  % antibiotic–antimycotic, 1  % l-glutamine, and 
10  mM HEPES (Life Technologies). HMVEC were used 
at P5–8, HFF were used at P14–22, and HaCaT were used 
at P40–46.
Cellular responses to injury in vitro
Cells were seeded in 6-well plates (VWR) and allowed to 
grow to confluence. 7–10  days later, concentric scratch 
wounds were created in post-confluent monolayers using 
stainless steel rakes that uniformly denude ~50 % of the 
resting population in each well [16]. Denuded cells (time 
0) were collected, lysed in RIPA buffer supplemented 
with a protease inhibitor cocktail (Sigma-Aldrich, St. 
Louis, MO), and mechanically disrupted by dounce 
homogenization on ice; 24  h after injury, the migrating 
cell populations were lysed and homogenized in the same 
manner. Equal amounts of protein from these homogen-
ates were mixed with reducing sample buffer containing 
a final concentration of 2  % β-mercaptoethanol (Sigma-
Aldrich), heated to 95  °C for 5  min, and separated by 
SDS-PAGE.
Peptide blot overlay
After SDS-PAGE, protein samples were transferred to 
Whatman Protran 0.1 μm pore size nitrocellulose mem-
branes (GE Healthcare, Little Chalfont, UK) and blocked 
for 1  h at room temperature with a protein-free block-
ing solution (Life Technologies). Membranes were then 
overlaid with protein-free blocking solution (Life Tech-
nologies) containing FITC-conjugated Comb1 peptide 
(200 nM, synthesized by Biomatik, Cambridge, ON) and 
incubated for 1 hour at room temperature with end-over-
end rotation, protected from light. Membranes were 
washed three times in PBS, and peptides were cross-
linked to putative receptors using 2  mM 1-ethyl-3-(3-
dimethylaminopropyl)carbodiimide hydrochloride (EDC, 
Life Technologies) and 2  mM  N-hydroxysuccinimide 
(NHS, Life Technologies) for 15  min at room tempera-
ture. Cross-linking was quenched by addition of three 
volumes of 200  mM glycine, 20  mM Tris–HCl, pH 7.5, 
for 3 min at room temperature. Membranes were washed 
in TBS and blocked overnight at 4  °C in protein-free 
blocking solution. Western blotting was performed using 
goat anti-FITC (1:100, Life Technologies) overnight at 
4  °C, followed by incubation with horseradish peroxi-
dase-conjugated donkey anti-goat secondary antibody 
(1:2000, Santa Cruz Biotechnology, Santa Cruz, CA), and 
developed using Clarity ECL western blotting substrate 
(BioRad, Hercules, CA). Digital imaging of Western blots 
was performed using a BioSpectrum Imaging System 
with VisionWorks software (UVP, Upland, CA).
Quantitative molecular analyses
RNA isolation
Total RNA was isolated from compartments of diabetic 
porcine wounds (adjacent, unwounded dermis and epi-
dermis, hypodermis, and granulation tissue) by homog-
enization in TRIzol (Life Technologies) and purification 
with RNEasy mini columns (Qiagen).
Quantitative real‑time PCR
One microgram RNA was reverse transcribed using the 
Quantitect Reverse Transcription kit (Qiagen). Reactions 
containing 5 ng cDNA were prepared in duplicate using 
Taqman probes and Taqman Gene Expression Master 
Mix (Life Technologies) according to the manufacturer’s 
instructions, and PCR was performed using an iCycler 
iQ5 real-time PCR detection system (BioRad). Relative 
mRNA expression was determined following normaliza-
tion to beta-actin or RPL32 using the 2−∆∆Ct method.
Data analysis and statistics
Excisional wounding experiments were performed a 
total of seven times; 7-days peptide treatments were per-
formed five times, and 3-days peptide treatments were 
performed twice. In all quantitative analyses, mean val-
ues were compared for each treatment group on day 3 
and 7 post-wounding, and all data are expressed as fold 
change relative to saline controls on each day  ±  SEM. 
All statistical analyses were performed using an unpaired 
Student’s t test. Peptide blot overlays were performed at 
least three times.
Results
Comb1 and UN3 enhance wound‑healing 
re‑epithelialization and angiogenesis in diabetic swine
Our past work demonstrates that the matrix- and 
plasma-derived peptides, Comb1 and UN3, stimulate 
capillary endothelial cell proliferation and morpho-
genesis, keratinocyte migration, and produce complete 
wound closure with highly vascularized granulation tis-
sue in murine models of impaired healing [12, 13]. As 
a result, we interrogated whether comparable doses of 
these same peptides induce wound-healing re-epitheli-
alization, angiogenesis, and granulation tissue formation 
in a diabetic porcine model of impaired healing. Histo-
morphometric analyses following full thickness exci-
sional wounding reveal that 3 days of peptide treatment 
(Fig.  1b) significantly increases re-epithelialization by 
75  % compared to saline (Fig.  1a, quantified in Fig.  1e). 
By day 7, peptide-treated wounds (Fig. 1d) demonstrate 
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a 26 % increase in wound closure over controls (Fig. 1c, 
quantified in Fig. 1e, p = 0.17). Importantly, there is no 
appreciable difference between the width of peptide- and 
saline-treated wounds at either time point, suggesting 
Comb1 and UN3 do not alter wound contraction. Addi-
tionally, quantitative immunohistochemistry of heparan 
sulfate proteoglycan (HPSG) and CD31 in diabetic por-
cine wounds reveals 3 days of peptide treatment (insets, 
Fig.  1a, b) significantly triples granulation tissue area 
and vascular density versus saline-treated controls, and 
7  days of peptide treatment (insets, Fig.  1c, d) signifi-
cantly increases these parameters by 30 and 80 %, respec-
tively (Fig. 1e).
Comb1 interactions depend on cell type and injury status
As our results indicate Comb1, alone, or in combination 
with UN3, stimulates wound-healing re-epithelializa-
tion, angiogenesis, and granulation tissue formation, we 
Fig. 1 Comb1 and UN3 enhance wound-healing re-epithelialization and angiogenesis in diabetic swine. (a–d) Representative trichrome staining 
of wounds treated with saline for 3 days (a) or 7 days (c) and Comb1 + UN3 (b, d). Scale bar (black) denotes 1 mm in all photomicrographs of tri-
chrome-stained tissues, and the yellow line denotes the linear distance traversed by migrating keratinocytes. Representative HSPG (green) and CD31 
(red) co-staining for each treatment condition and time point are displayed as insets in upper right of each panel; scale bar (white) denotes 100 μm, 
and the dashed white line in the insets of (a) and (b) denotes the lateral border between injured and non-injured tissue. Data in (e) are expressed 
as mean wound re-epithelialization, width, granulation tissue area, and microvascular density normalized to saline-treated controls on each day, 
±SEM, *p ≤ 0.05, **p ≤ 0.01. For re-epithelialization and wound width measurements: Saline day 3, n = 9; Comb1 + UN3 day 3, n = 10; Saline day 
7, n = 18; Comb1 + UN3 day 7, n = 24. For granulation tissue area and microvascular density measurements: Saline day 3, n = 3; Comb1 + UN3 day 
3, n = 5; Saline day 7, n = 9; Comb1 + UN3 day 7, n = 10
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interrogated Comb1 localization patterns in diabetic por-
cine wounds. FITC-Comb1 labels migratory keratinocytes, 
along with stromal and vascular cells present within gran-
ulation tissue at the wound margin in sections of diabetic 
porcine wounds (Fig.  2a). FITC-Comb1 also labels these 
cells several millimeters distal to the site of injury. Thus, 
Comb1 interacts with dermal and epidermal cell popula-
tions actively engaged in proliferative and migratory pro-
cesses, as well as non-injured, non-migratory cells.
Based on these tissue localization patterns, we next 
investigated whether Comb1 interacts with distinct pro-
teins in post-confluent HMVEC, HaCaT, and HFF, and in 
migratory cells post-injury. FITC-Comb1 binds multiple 
proteins, some of which are uniquely present in injured cell 
populations in  vitro, including a ~250  kDa protein com-
mon to all injured cell populations tested (Fig. 2b). FITC-
Comb1 also binds proteins of ~100 and ~67 kDa in injured 
HaCaT and HMVEC that are not present in injured HFF, 
as well as proteins in confluent and post-injury HFF that 
do not appear in the other cell populations.
Comb1 and UN3 induce multiple tissue repair pathways
In parallel, to determine the molecular underpinnings of 
the Comb1- and UN3-driven wound-healing responses, 
we employed quantitative real-time PCR (qPCR) to ana-
lyze mRNA expression of mediators of angiogenesis, 
stem and endothelial progenitor cell chemotaxis, fibro-
blast activation and dermal ECM remodeling, and epi-
thelialization within granulation tissue, hypodermis, and 
the dermal and epidermal compartments immediately 
adjacent to the cutaneous injury.
Comb1 and UN3 increase steady‑state mRNA levels 
of pro‑angiogenic effectors after injury
In granulation tissue (Fig.  3a), we observe significant 
increases in VEGFA (80 %) and FGF2 (80 %) expression fol-
lowing 3 days of peptide treatment, compared to controls. 
After 7 days of peptide treatment, VEGFA remains signifi-
cantly elevated over saline-treated controls (30 %), and FGF2 
continues to significantly increase (2.1-fold). Analysis of 
combined VEGFR1/2 expression reveals a 2.1-fold increase 
in expression at day 3, and a 20 % increase in mRNA steady 
state expression at day 7, similar to VEGFA trends.
In hypodermal tissues (Fig.  3b), 3  days of peptide 
treatment induces a twofold increase in VEGFA, which 
remains elevated at day 7. Combined VEGFR1/2 expres-
sion levels are significantly elevated (2.4-fold) over saline 
controls at day 3 and day 7 (50 %). FGF2 is elevated over 
saline controls on day 3 by 50  % (p  =  0.11), while we 
observe no difference in hypodermal FGF2 expression 
at day 7. The dermal and epidermal tissues immediately 
adjacent to the wound display significantly increased 
VEGFA (2.2-fold), VEGFR1/2 (2.1-fold) and FGF2 (90 %) 
following 3  days of peptide administration (Fig.  3c). 
However, by day 7, we detect a statistically insignificant 
elevation in VEGFA (30 %, p = 0.17), and observe no dif-
ferences in VEGFR1/2 or FGF2 expression compared to 
saline treatment.
Fig. 2 Cytological and biochemical characteristics of FITC-Comb1 interactions. a FITC-conjugated Comb1 binds to blood vessels and keratinocytes. 
Fresh frozen sections from diabetic porcine wounds were blocked with 5 % normal goat serum in PBS, then incubated in block solution alone or 
containing 100 nM FITC-Comb1, followed by immunofluorescence microscopy using anti-FITC (1:200, Life Technologies). Image analysis reveals that 
FITC-Comb1 binds to wound-associated keratinocytes, stromal, and vascular cells, as well as keratinocytes distal to the cutaneous defect. Image of 
trichrome-stained tissue provided for location context. Scale bar denotes 500 μm in all panels. b FITC-conjugated Comb1 ligates with numerous 
proteins expressed in HMVEC, HaCaT, and HFF. Whole cell lysates were prepared from cells denuded from post-confluent monolayers, representing 
the control/resting state of the cells, and actively recovering cells collected 24 h after injury, then separated by SDS-PAGE. Gels were transferred to 
nitrocellulose membranes, overlaid with 200 nM FITC-Comb1, and cross-linked to putative receptors and interactors using 2 mM EDC and 2 mM 
NHS. Interactors were detected using by western blotting with an anti-FITC antibody
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Comb1 and UN3 stimulate the SDF1α‑CXCR4 chemotactic 
axis
SDF1α and its receptor, CXCR4, comprise a highly con-
served system that regulates bone marrow and periph-
eral stem cell mobilization to injury sites, including 
endothelial progenitor cells [17], and local SDF1α eleva-
tions have been linked to improved healing in diabetic 
wounds [18, 19]. Given the roles of endothelial progeni-
tor homing and differentiation in wound vasculariza-
tion downstream of SDF1α, we asked whether Comb1 
Fig. 3 Comb1 and UN3 promote mRNA expression of key angiogenic mediators. Sample cDNAs (equivalent of 5 ng mRNA) reverse transcribed 
from granulation tissue (a), hypodermis (b), and portions of adjacent dermis and epidermis (c) were used as template, and each sample was nor-
malized using β-actin (granulation tissue) or RPL32 (hypodermis, adjacent dermal and epidermal tissues) as a reference gene. All expression levels 
were calculated using the 2−∆∆Ct method of relative quantitation. All data are expressed as relative abundance over saline-treated controls, ± SEM. 
*p ≤ 0.05, **p ≤ 0.01, ***p ≤ 0.005, ****p ≤ 0.001. Saline day 3, n = 4; Comb1 + UN3 day 3, n = 10; Saline day 7, n = 16; Comb1 + UN3 day 7, 
n = 19
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and UN3 impact SDF1α and CXCR4 expression in dia-
betic swine wounds. Peptide treatment increases SDF1α 
mRNA in granulation tissue and the hypodermis, and 
increases CXCR4 mRNA in all tissue compartments after 
3  days of treatment (Fig.  4a–c). After 7  days of peptide 
treatment, granulation tissue SDF1α and CXCR4 mRNA 
remain significantly elevated over controls, while we 
detect no differences in these factors in either the hypo-
dermis or the adjacent unwounded compartment.
Comb1 and UN3 enhance ECM‑remodeling enzyme mRNA 
expression
Peptide treatment significantly increases granulation 
tissue MMP2 (1.5-fold), MMP9 (2.4-fold), and TIMP1 
mRNA (3.7-fold) after 3  days of treatment, compared to 
saline (Fig. 5a); these peptide-mediated inductions persist 
through 7 days of treatment (2.2, 2.7, and 1.4-fold, respec-
tively). While we observe similar elevations in hypodermal 
MMP2 (1.6-fold), MMP9 (3.7-fold, p = 0.08), and TIMP1 
(2.1-fold) after 3 days of treatment (Fig. 5b), these changes 
are not statistically significant. Within the adjacent dermal 
and epidermal compartments (Fig.  5c), we detect signifi-
cant elevations in MMP2 (1.8-fold) and TIMP1 (3.8-fold) 
after 3 days of treatment, compared to saline; while pep-
tide treatment increases MMP9 expression by 5.5-fold, this 
change is not statistically significant (p = 0.16). The pep-
tide-associated increases in MMP9 mRNA in the hypoder-
mis and the adjacent uninjured dermal compartment after 
7 days of peptide treatment are not statistically significant, 
and we observe little difference in MMP2 or TIMP1. We 
also investigated transforming growth factor-β1 (TGF-β1) 
mRNA expression, as a major regulator of fibroblast acti-
vation and ECM synthesis, among other functions. TGF-
β1 mRNA is significantly increased after 3 days of peptide 
treatment in all wound compartments analyzed. However, 
this induction is transient, as we observe no difference in 
TGF-β1 expression after 7 days of treatment. Thus, Comb1 
and UN3 induce MMP and TIMP expression, and stimu-
late early TGF-β1 mRNA expression.
Comb1 and UN3 drive mRNA expression of keratinocyte 
signaling pathways
In granulation tissue, 3 days of peptide treatment yields 
a 70 % increase HB-EGF mRNA, and EGF mRNA is sig-
nificantly elevated (2.4-fold) after 7  days of treatment 
(Fig. 6a). While peptide treatment increases granulation 
tissue EGFR mRNA on day 3 and day 7 (20 and 30  %, 
respectively), these changes are not statistically signifi-
cant. In the hypodermis, Comb1 and UN3 increase HB-
EGF mRNA after 3 days of treatment, and EGFR mRNA 
after 7 days of treatment (Fig. 6b). In the adjacent dermal 
and epidermal tissues (Fig.  6c), we detect increases in 
EGF (2.6-fold, p = 0.18) and HB-EGF (2.6-fold, p = 0.07) 
after 3  days of peptide treatment, and a 90  % increase 
in EGF mRNA (p = 0.07) after 7 days of treatment. We 
observe a 50  % increase in EGFR expression on day 3, 
but no change in EGFR mRNA on day 7 in this compart-
ment. We detect no difference in TGF-αmRNA expres-
sion between peptide- and saline-treated wounds in any 
of the tissue portions analyzed, and no TGF-α mRNA in 
hypodermal tissues. These data suggest Comb1 and UN3 
induce specific EGF members in a time- and tissue com-
partment-dependent manner.
Fig. 4 Comb1 and UN3 induce SDF1α and CXCR4 mRNA expres-
sion. Sample cDNAs (equivalent of 5 ng mRNA) reverse transcribed 
from granulation tissue (a), hypodermis (b), and portions of adjacent 
dermis and epidermis (c) were used as template, and each sample 
was normalized using β-actin (granulation tissue) or RPL32 (hypoder-
mis, adjacent dermal and epidermal tissues) as a reference gene. All 
expression levels were calculated using the 2−∆∆Ct method of relative 
quantitation. All data are expressed as relative abundance over saline-
treated controls, ±SEM. *p ≤ 0.05, **p ≤ 0.01. Saline day 3, n = 4; 
Comb1 + UN3 day 3, n = 10; Saline day 7, n = 16; Comb1 + UN3 day 
7, n = 19
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Discussion
DFU are a leading cause of limb amputations [20], yet 
there is a limited arsenal of FDA-approved medications 
that effectively induce angiogenesis and achieve total 
wound closure. Indeed, a 2015 Cochrane systematic 
review [21] determined there is insufficient evidence to 
either support or refute using becaplermin and other 
recombinant growth factors as standard treatments for 
DFU. In our efforts to create advanced wound-healing 
therapeutics to meet the rising clinical needs, our lab cre-
ated two bioactive peptides, Comb1 and UN3, that foster 
complete wound closure in pre-clinical murine models of 
cyclophosphamide-dependent healing impairments [13]. 
Thus, we hypothesized these two peptides would stimu-
late healing responses in a pre-clinical model of deficient 
healing in diabetes. Our present study confirms this 
hypothesis and extends our previous results, as Comb1 
and UN3 markedly enhance wound-healing angiogen-
esis and re-epithelialization in full-thickness cutaneous 
wounds on the backs of diabetic swine. Consistent with 
these observations, qPCR analyses reveal that Comb1 
and UN3 increase mRNA expression of growth factors 
and cytokines involved in angiogenesis, progenitor cell 
mobilization, epithelialization, fibroblast activation, and 
enzymes regulating ECM remodeling, lending insights 
into the peptides’ mechanisms of action.
Comb1 and UN3 induce balanced MMP/TIMP expression 
in diabetic porcine wounds
Chronic wounds exhibit depressed TIMP expression 
concomitant with MMP and neutrophil elastase lev-
els 50–100 times greater than those that heal acutely [6, 
22]. This profound imbalance in the protease-to-inhibi-
tor ratio radically disrupts ECM turnover and degrades 
growth factors, thus undermining the dynamic reciproc-
ity between cells and their microenvironment required 
for wound resolution [7, 8, 23]. Further, the chronic 
wound protease burden may reduce the efficacy of 
growth factor-based therapeutics, including becaplermin 
[9, 24]. Accordingly, treatment paradigms aimed at cor-
recting the protease imbalance have emerged as prom-
ising tactics, including therapeutics that normalize the 
protease-to-inhibitor ratio [25], and rationally designed 
molecular medicines that either resist MMP- and neutro-
phil elastase-dependent cleavage, or maintain their bio-
activity after proteolysis.
Protease overabundance is widely considered a princi-
pal factor underlying wound chronicity [6]. Importantly, 
Comb1 and UN3 treatment not only promotes wound 
healing but also significantly enhances MMP2, MMP9, 
and TIMP1 mRNA expression (Fig. 5a–c). Inducing these 
factors, together, may aid in restoring the physiologic 
MMP-TIMP balance, yielding regulated matrix remod-
eling and preventing degradation of growth factors and 
their cognate receptors that enable downstream angio-
genesis and re-epithelialization. Clinical assessment of 
wound proteases and inhibitors may represent a major 
advance in monitoring wound resolution, in addition 
Fig. 5 Comb1 and UN3 stimulate balanced inductions in dermal 
matrix remodeling factors. Sample cDNAs (equivalent of 5 ng mRNA) 
reverse transcribed from granulation tissue (a), hypodermis (b), and 
portions of adjacent dermis and epidermis (c) were used as template, 
and each sample was normalized using β-actin (granulation tissue) 
or RPL32 (hypodermis, adjacent dermal and epidermal tissues) as a 
reference gene. All expression levels were calculated using the 2−∆∆Ct 
method of relative quantitation. All data are expressed as relative 
abundance over saline-treated controls, ±SEM. *p ≤ 0.05, **p ≤ 0.01, 
***p ≤ 0.005, ****p ≤ 0.001. Saline day 3, n = 4; Comb1 + UN3 day 3, 
n = 10; Saline day 7, n = 16; Comb1 + UN3 day 7, n = 19
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to identifying mechanisms of chronicity. Indeed, Ser-
ena, et  al. [26] recently developed methods to correlate 
global wound protease activity with healing status. At 
the same time, because chronic wounds may possess 
therapeutically responsive regions in addition to stalled, 
healing-incompetent areas [27], quantitative molecular 
profiling of local MMP/TIMP ratios through advanced 
transcriptional analyses could serve as a rapid and pow-
erful diagnostic to precisely delineate margins between 
healing and non-healing tissues, direct treatment, and 
Fig. 6 Comb1 and UN3 modulate expression of specific EGF family members to achieve re-epithelialization. Sample cDNAs (equivalent of 5 ng 
mRNA) reverse transcribed from granulation tissue (a), hypodermis (b), and portions of adjacent dermis and epidermis (c) were used as template, 
and each sample was normalized using β-actin (granulation tissue) or RPL32 (hypodermis, adjacent dermal and epidermal tissues) as a reference 
gene. All expression levels were calculated using the 2−∆∆Ct method of relative quantitation. All data are expressed as relative abundance over 
saline-treated controls, ±SEM. *p ≤ 0.05, **p ≤ 0.01. Saline day 3, n = 4; Comb1 + UN3 day 3, n = 10; Saline day 7, n = 16; Comb1 + UN3 day 7, 
n = 19
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monitor healing progress. Future studies are needed to 
identify the range of regional MMP/TIMP mRNA ratios 
that might best determine healing outcomes.
In addition to stimulating MMP and TIMP mRNA 
expression, in silico protease substrate analyses using 
PROSPER and CleavPredict, online bioinformatics tools 
that predict protease targets [28, 29], suggest neither 
Comb1 nor UN3 are susceptible to MMP-mediated deg-
radation. And, while ExPASY PeptideCutter [30] reveals 
neutrophil elastase recognition sites in Comb1 and UN3, 
the products arising from such cleavages (Table  1) are 
nearly identical to the individual bioactive peptides that 
were combined to create these entities [12, 13]. Hence, 
these peptides may be uniquely suited to foster healing 
despite the protease-rich chronic wound microenviron-
ment, and it may be important to determine the in vivo 
efficacy of the original peptides used to create the combi-
natorial peptides tested in our present study.
Intriguingly, neutrophil elastase is also predicted to lib-
erate a fragment from the Comb1 C-terminal (EGLEPG) 
corresponding to a broadly bioactive xGxxPG con-
sensus sequence first identified in elastin degradation 
products [31]. Peptides matching this motif, including 
VGVAPG and EGFEPG, not only regulate MMP and 
TIMP expression in endothelial cells, dermal fibroblasts, 
and macrophages, but also stimulate migratory, pro-
liferative, and morphogenic behaviors in these cells, as 
well as in keratinocytes [32–35]. Additionally, VGVAPG 
enhances CXCR4/SDF1α mRNA and protein expres-
sion in melanoma cell lines [36], further highlighting the 
chemotactic and potential immunomodulatory nature 
of such peptides. In  vivo, xGxxPG peptides stimulate 
angiogenesis [32], and Attia-Vigneau, et  al. [37] dem-
onstrated that a “multi-headed” synthetic peptide con-
taining three VGVAPG repeats promotes regeneration 
in cultured human dermal explants. Curiously, PRP, the 
source of the fragments constituting UN3, is also known 
to induce MMPs as well as TIMPs in  vitro and in  vivo 
[38–40]. These reports, together with our data, suggest 
multiple mechanisms through which xGxxPG-contain-
ing and PRP-derived peptides may regulate tissue repair, 
including protease/inhibitor modulation and progeni-
tor cell chemotaxis, and to our knowledge this is the first 
report of such peptides stimulating healing in a large ani-
mal model of diabetic wounds.
Multiple cells and receptors may mediate Comb1 
bioactivity
As several different cell populations bind and transduce 
signals from elastin-derived peptides such as EGLEPG, 
notably, Comb1 localizes to keratinocytes, fibroblasts and 
vascular cells in areas of swine wounds undergoing active 
remodeling and non-migratory cells several millimeters 
distal to the site of injury. Further, HMVEC, HaCaT and 
HFF display similarities in the molecular weights of pro-
tein effectors that interact with Comb1 at baseline and 
during injury repair. The presence of ~250 and ~67  kD 
proteins cross-linked with FITC-Comb1 in all cells tested 
suggests there may be several, common receptors for this 
peptide across cell lineages. Indeed, vascular endothe-
lial cells, fibroblasts, keratinocytes, and immune cells 
respond to elastin-derived peptides through multiple 
receptors, including the elastin binding protein complex, 
cell surface-associated galectin-3, and integrin αvβ3, all 
of which regulate cell migration, proliferation and angio-
genesis [32, 36, 41]; additionally, as Comb1 is composed 
of fibrillin and tenascin X fragments, it is possible that 
this peptide ligates with several receptors that interact 
with these ‘parent’ matrix molecules. Moreover, injury-
dependent alterations in cell-specific receptor profiles 
may account for the observed differences in Comb1 bind-
ing patterns. For example, whereas post-injury endothe-
lial integrin αvβ3 expression supports angiogenesis via 
adhesion to fibrin in the hemostatic plug, the absence 
of αvβ3 in keratinocytes, coupled with αvβ6 emergence 
and β1 subunit relocalization, contribute to their specific 
post-injury migration patterns [7]. Accordingly, advanced 
wound-healing therapeutics may be rationally designed 
to selectively activate injury-upregulated receptors, in 
order to potentiate cell migration, proliferation and angi-
ogenesis and limit off-target effects. By extension, antag-
onists of these receptors might restrict such processes in 
numerous pathologies, including aberrant neovasculari-
zation in proliferative diabetic retinopathy and cancers, 
as well as proteolytic and migratory cascades involved 
in tumor metastasis. Hence, our future experiments will 
aim to identify and characterize the functions of the 
putative Comb1 receptors.
Conclusions
In summary, Comb1 and UN3 promote wound resolu-
tion in a pre-clinical, large animal model of impaired 
diabetic healing, supporting results obtained previously 
in our cell- and rodent-based studies [12, 13]. These 
Table 1 Bioactive matrix and  PRP-derived peptide 
sequences and predicted cleavage products
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peptides increase steady-state mRNA levels of factors 
that drive angiogenesis, epithelialization, progenitor and 
immune cell chemotaxis, and ECM turnover in  vivo, 
critically including balanced MMP and TIMP induction 
that may support tissue repair. Additionally, our findings 
suggest Comb1 and UN3 may have novel roles in fibro-
blast activation and immune cell function, which may 
be promising areas of future exploration. As peptide-
dependent vascularization and wound closure are per-
haps attributable to signals transduced through multiple, 
injury-regulated receptors expressed on endothelial cells, 
keratinocytes, and fibroblasts, discerning the precise 
mechanisms of Comb1 and UN3 bioactivity remain areas 
of ongoing investigation.
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